Skip to main content
OpenTrials

Clinical trial condition

Paraproteinemias

Explore clinical trials studying Paraproteinemias. Study availability and eligibility vary by location and protocol.

52 public trials 12 recruiting studies
Refine in advanced search Browse all conditions

Paraproteinemias trial results

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)

NCT04504825

Conditions
AL Amyloidosis, Amyloidosis, Blood Protein Disorders, +13 more
Locations
  • Research Site Duarte, California, United States
  • Research Site Palo Alto, California, United States
  • Research Site San Francisco, California, United States
  • Research Site Weston, Florida, United States
View all 90 locations
View Trial Details
Active, not recruiting

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)

NCT04512235

Conditions
AL Amyloidosis, Amyloidosis, Blood Protein Disorders, +13 more
Locations
  • Research Site Scottsdale, Arizona, United States
  • Research Site Duarte, California, United States
  • Research Site Palo Alto, California, United States
  • Research Site San Francisco, California, United States
View all 110 locations
View Trial Details
Active, not recruiting

A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)

NCT03162536

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Chronic Disease, +41 more
Locations
  • Mayo Clinic Hospital ( Site 0140) Scottsdale, Arizona, United States
  • UCLA Hematology & Oncology ( Site 0017) Los Angeles, California, United States
  • Colorado Blood Cancer Institute ( Site 0225) Denver, Colorado, United States
  • University of Michigan ( Site 0018) Ann Arbor, Michigan, United States
View Trial Details
Active, not recruiting

Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma

NCT03236428

Conditions
Blood Protein Disorders, Hematologic Diseases, Hemic and Lymphatic Diseases, +8 more
Locations
  • Pacific Cancer Care Monterey, California, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • Beth Israel Deaconess Medical Center Boston, Massachusetts, United States
View Trial Details
Active, not recruiting

Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom

NCT02952508

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Central Nervous System Lymphoma, +36 more
Locations
  • Cellectar Biosciences site Los Angeles, California, United States
  • Cellectar Biosciences site Redlands, California, United States
  • Cellectar Biosciences site Washington D.C., District of Columbia, United States
  • Cellectar Biosciences site Jacksonville, Florida, United States
View all 52 locations
View Trial Details
Completed

Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma

NCT05804032

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Universitätsklinikum Krems Krems, Austria
  • Ordensklinikum Linz Linz, Austria
  • Landeskrankenhaus Feldkirch-Rankweil Rankweil, Austria
  • Universitätsklinikum der Paracelsus, 3. Med. Abteilung/Onkologie Ambulanz Salzburg, Austria
View all 91 locations
View Trial Details
Completed

A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.

NCT05228470

Conditions
BCMA, BCMA-CD3 Bispecific, Bispecific, +23 more
Locations
  • Fujian Medical University Union Hospital Fuzhou, Fujian, China
  • Guangdong Provincial People's Hospital Guangzhou, Guangdong, China
  • Nanfang Hospital of Southern Medical University Guangzhou, Guangdong, China
  • Sun Yat-sen University Cancer Center Guangzhou, Guangdong, China
View all 15 locations
View Trial Details

Related conditions